risk-adjusted safety analysis of pacritinib for patients with mf
Published 2 years ago • 249 plays • Length 1:31Download video MP4
Download video MP3
Similar videos
-
1:17
the use of pacritinib in thrombocytopenic patients with myelofibrosis undergoing allosct
-
4:48
an insight into the management of cytopenias in mf
-
1:15
potential approval of pacritinib for the treatment of myelofibrosis
-
1:46
the efficacy of pacritinib in patients with myelofibrosis who have both thrombocytopenia and anemia
-
0:54
study design for persist-2 and other upcoming trials of pacritinib
-
3:48
efficacy of momelotinib in thrombocytopenic patients with myelofibrosis from momentum
-
7:01
nico gagelmann, md, discusses the young eha session on early career advancement
-
4:22
discover versiti diagnostic labs, clinical trials and biomaterials | versiti
-
2:04
design and results of persist-1 trial of pacritinib for myelofibrosis
-
3:46
results of the phase iii persist-1 trial of pacritinib for myelofibrosis
-
1:54
fostamatinib and efgartigimod: novel agents in the treatment of itp
-
0:47
novel agents being explored for the treatment of immune-mediated ttp
-
2:50
phase i study of abbv383, a novel bcmaxcd3 bispecific antibody, in r/r multiple myeloma
-
0:52
rilzabrutinib: a novel promising btk inhibitor being explored in itp
-
1:39
update on a phase i/ii study of ziftomenib in patients with r/r aml
-
4:45
a first-in-human trial of linvoseltamab (regn5458) in r/r myeloma: updated phase i data
-
2:16
phase i study of donor-derived γδ t cells as relapse prophylaxis post haplo/cy
-
1:39
session highlights: the value of clinical hematology research groups
-
6:07
a crispr approach to hematological research
-
2:03
prognostic significance of molecular mrd in npm1-mutated aml treated with venetoclax-based therapy
-
1:35
phase i study of plx51107, a novel bet inhibitor, in combination with azacitidine in r/r mds and aml
-
2:12
novel agents of interest for the treatment of bpdcn